51 results about "Streptococcus pneumoniae serotype" patented technology

A shortened process for producing a solution containing substantially purified capsular polysaccharides from a cellular Streptococcus pneumoniae lysate broth is described. Ultrafiltering and diafiltering a clarified S. pneumoniae lysate followed by pH adjustment to less than 4.5, preferably about 3.5, precipitated at least 98% of the protein in the solution without seriously affecting polysaccharide yield. Furthermore, following ultrafiltration and diafiltration and acidification to a pH of less than 4.5, filtration using activated carbon precipitated at least 90% of remaining protein without seriously affecting polysaccharide yield. Exemplary, non-limiting S. pneumoniae serotypes that can be purified using the shortened process of the invention are 1, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. In one embodiment, the Streptococcus pneumoniae cells are lysed using deoxycholate sodium (DOC), while in another embodiment the lytic agent is a non-animal derived lytic agent such as N-lauryl sarcosine sodium (NLS).

The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.

The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

The present invention relates to molecular methods of serotyping Streptococcus pneunoniae, as well as polynu-cleotides useful in such methods. These methods rely on analysing at least a portion of the nucleotide sequence between the 3′ end of the cpsA gene and the 5′ end of the cpsB gene, and/or analysing at least a portion of the szy and/or wzx gene(s).

The invention provides a method for carrying out serotyping on streptococcus pneumoniae by using MLPA (multiplex ligation dependent probe amplification). The method comprises the following steps of: firstly, extracting a sample genome DNA of streptococcus pneumoniae to be detected; carrying out pre-amplification on the extracted genome DNA by using a PCR pre-amplification primer; carrying out hybridization on pre-amplification products of the genome DNA by using an MLPA probe; adding a corresponding fluorescence detecting probe in a reaction system; connecting hybridized MLPA probes by using ligase, and carrying out PCR amplification on the hybridized and connected MLPA probes by using an MLPA universal amplification primer; and analyzing PCR products by using a multicolor fluorescence dissolution curve, so that the serotyping on streptococcus pneumoniae can be realized. The detecting method disclosed by the invention is good in specificity and high in sensitivity; according to the method, 10 kinds of serotypes can be subjected to genotyping simultaneously just in 2-4 hours, so that multiple uncapping operations in traditional MLPA detection are avoided, and the pollution possibility is reduced, therefore, the method can meet high-throughput sample detection, and is especially applicable to inspection departments.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Streptococcus pneumoniae serotypes.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these N serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR. The present invention further provides polysaccharide-protein conjugates in which capsular polysaccharides from one or more of these serotypes are conjugated to a carrier protein such as CRM197. Polysaccharide-protein conjugates from one or more of these serotypes may be included in multivalent pneumococcal conjugate vaccines having polysaccharides from multiple additional Steptococcus pneumoniae serotypes.

The invention relates to one kind of gene chip used in the pneumonia streptococcus blood serum examination and its examination method and the reagent box used thereof. The gene chip includes the solid phase carrier and the oligonucleotide probe fixed on this carrier. The probe includes the DNA fragment selected from the streptococcus pneumoniae 16s rDNA and the DNA fragment selected from the polyase gene of streptococcus pneumoniae. Use designed primer to enlarge and mark the gene group of the sample to be detected, then to hybrid the gene group using the biological chip, the different type of serum of the streptococcus pneumoniae can be detected.

The invention discloses a 16-valent streptococcus pneumoniae conjugate vaccine composition. The vaccine composition is obtained in a manner that streptococcus pneumoniae capsular polysaccharide afterseparation and purification and carrier protein are subjected to coupling combination to be mixed, wherein the capsular polysaccharide includes 16 streptococcus pneumoniae serotypes of 1, 2, 3, 4, 5,6A, 6B, 7F, 9V, 11A, 14, 15B, 18C, 19A, 19F and 23F. The 16-valent streptococcus pneumoniae conjugate vaccine composition can cover most of common pathogenic bacterial types or drug-resistance bacterial types of our country, and has the broad-spectrum and efficient protection effect on high-risk susceptible populations such as new-born infants, old people and children under two years old.

The invention discloses S. pneumonia in the technical field of bio-pharmacy. The S. pneumonia comprises an S. pneumonia serum type strain, wherein the S. pneumonia serum type strain includes one or a plurality of kinds of capsular polysaccharide generating inhabiting genes with integral lack, partial lack, sequence point mutation or sequence point lack. When the capsular polysaccharide generating inhabiting genes have one or a plurality of kinds of changes of partial lack, sequence point mutation or lack, the function and the activity of the SPD-0064 genes or coded products of the SPD-0064 genes can be influenced; the goal of interfering or inhibiting the combination of SPD-0064 gene coding products and capsular polysaccharide gene clusters is achieved, so that the transcription function of the capsular polysaccharide gene clusters is interfered or damaged; the capsular polysaccharide yield is finally increased.

The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides having phosphodiester linkages between saccharide repeat units. In certain methods, CO₂ is supplied to a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharide serotypes containing phosphodiester linkages between saccharide repeat units. Exemplary Streptococcus pneumoniae serotypes containing a phosphodiester linkage between saccharide repeat units include serotypes 6A, 6B, 19A, and 19F. Supplying CO₂ to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO₂.